Natco Pharma advances Adcock Ingram acquisition after shareholder vote

Natco Pharma Limited announced an update on its proposed acquisition of shares in Adcock Ingram Holdings Limited following a General Meeting held on October 9, 2025. The scheme resolution, crucial for approving the acquisition, passed with 98.66% of votes cast in favor and 1.34% against. These votes represented 73.16% of the total issued shares entitled to be voted, with 0.01% abstained.

The acquisition plan involves Natco Pharma South Africa Proprietary Limited acquiring all issued ordinary shares in Adcock Ingram not already held by Natco, Bidvest, or as treasury shares. This follows a firm intention announcement released on July 23, 2025.

Once the scheme becomes unconditional and receives a compliance certificate from the Takeover Regulation Panel of South Africa, Adcock Ingram's ordinary shares will be delisted from the JSE Limited. Shareholders recorded on the scheme record date will receive a per share scheme consideration of ZAR 75.00 per Adcock Ingram share.